FDA Permits Sale Of Ranbaxy's Drug for Diabetes Cure in the US Market
Mumbai: Ohm Laboratories, Ranbaxy’s US subsidiary has received the US Food and Drug Administration's (FDA) authorization to sell Metformin Hydrochloride tabs that are exclusively intended for curing diabetes.
The Florida-based Ranbaxy Pharmaceuticals, a wholly-owned subsidiary of Ranbaxy Laboratories also said that it received the permission to sell Metformin Hydrochloride pills in various strengths of 500 mg, 850 mg and 1,000 mg in the US market through Ohm Laboratories.
Ohm Laboratories was established mutually by Ipca Laboratories and Ranbaxy Pharmaceuticals. Ipca Laboratories, which is building a novel constructing unit at Indore, would produce Metformin Hydrochloride in India.
According to industry statistics, the twelve-monthly US sales of the drug stand at $379 million.